Page 18 - JCTR-11-1

Journal of Clinical and
Translational Research Cannabinoids for cannabis use disorder

a significant reduction in cravings, and withdrawal References
symptoms, and an increase in treatment retention. One 1. UNODC. World Drug Report 2023. United Nations
study suggests that CBD might reduce cannabis use and Publication; 2023. Available from: https://www.unodc.org/
withdrawal symptoms, and increase abstinence. Other unodc/en/data-and-analysis/world-drug-report-2023.html
CB receptor agonists, such as dronabinol and nabilone, [Last accessed on 2024 Aug 1].
showed limited or no therapeutic retention. Moreover, CBs
were well tolerated and may decrease cannabis use with 2. Sherman BJ, McRae‐Clark AL. Treatment of cannabis
use disorder: Current science and future outlook.
no significant increase in adverse effects among cannabis Pharmacotherapy. 2016;36(5):511-535.
users seeking treatment. However, the small number of
studies summarized in this review need to be interpreted doi: 10.1002/phar.1747
with caution. While there is interest in the clinical potential 3. American Psychiatric Association (APA). Diagnostic and
of CBs for this purpose, it is important to note that their Statistical Manual of Mental Disorders. 5 ed. Washington,
th
effectiveness and clinical indication are not yet established. DC: American Psychiatric Association; 2022.
Further research is necessary to standardize assessment 4. Leung J, Chan GCK, Hides L, Hall WD. What is the
methods for this population, producing stronger evidence prevalence and risk of cannabis use disorders among people
to support or not the therapeutic use of cannabis for who use cannabis? A systematic review and meta-analysis.
treating CUD. Addict Behav. 2020;109:106479.
Acknowledgments doi: 10.1016/j.addbeh.2020.106479
5. Dawson D, Stjepanović D, Lorenzetti V, Cheung C, Hall W,
None. Leung J. The prevalence of cannabis use disorders in people
who use medicinal cannabis: A systematic review and meta-
Funding analysis. Drug Alcohol Depend. 2024;257:111263.
None. doi: 10.1016/j.drugalcdep.2024.111263
Conflict of interest 6. Hasin DS. US epidemiology of cannabis use and associated
problems. Neuropsychopharmacology. 2018;43(1):195-212.
All authors declare no relationships that could be doi: 10.1038/npp.2017.198
considered conflicts of interest.
7. Bahji A, Stephenson C, Tyo R, Hawken ER, Seitz DP.
Author contributions Prevalence of cannabis withdrawal symptoms among
people with regular or dependent use of cannabinoids:
Conceptualization: Camila Mari Yamada, Fernanda A systematic review and meta-analysis. JAMA Netw Open.
Valeriano Zamora 2020;3(4):e202370.
Writing–original draft: Camila Mari Yamada, Ana Clara
Felix de Farias Santos, Lorhayne Kerley Capuchinho doi: 10.1001/jamanetworkopen.2020.2370
Scalioni Galvao, Patrícia Almeida Jacob Moreno, 8. Connor JP, Stjepanović D, Le Foll B, Hoch E, Budney AJ,
Nicole dos Santos Pimenta, Joao Pedro Costa Esteves Hall WD. Cannabis use and cannabis use disorder. Nat Rev
Almuinha Salles, Andres Villca Zamora Dis Primer. 2021;7(1):16.
Writing–review & editing: Camila Mari Yamada, Ana Clara doi: 10.1038/s41572-021-00247-4
Felix de Farias Santos, Fernanda Valeriano Zamora, 9. Schlosburg JE, Carlson BLA, Ramesh D, et al. Inhibitors
Andres Villca Zamora
of endocannabinoid-metabolizing enzymes reduce
Ethics approval and consent to participate precipitated withdrawal responses in THC-Dependent
mice. AAPS J. 2009;11(2):342-352.
Not applicable. doi: 10.1208/s12248-009-9110-7

Consent for publication 10. European Monitoring Centre for Drugs and Drug Addiction.
European Drug Report 2023. Publications Office; 2023.
Not applicable. Available from: https://data.europa.eu/doi/10.2810/161905
[Last accessed on 2024 Jun 22].
Availability of data
11. Bahji A, Meyyappan AC, Hawken ER, Tibbo PG.
All data supporting the findings of this meta-analysis are Pharmacotherapies for cannabis use disorder: A systematic
available and can be provided by the corresponding author review and network meta-analysis. Int J Drug Policy.
upon reasonable request. 2021;97:103295.

Volume 11 Issue 1 (2025) 12 doi: 10.36922/jctr.24.00066